ACTG A5164

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者的研究机构。 A5164是一项随机、IV期研究，旨在评估在出现急性艾滋病相关机会性感染（OI）或严重细菌感染（BI）的晚期免疫缺陷综合征受试者中立即与延迟抗逆转录病毒治疗（ARV治疗或治疗，或ART）策略。 本研究将分为两个阶段和两个分支。 所有受试者将进入第1步，并随机分配至急性OI/BI治疗开始后14天内接受ART（“立即”组或A组）或延迟接受ART（“延迟”组或B组）。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. A5164 is a randomized, phase IV study of the strategy of immediate versus deferred antiretroviral therapy (ARV therapy or treatment, or ART) in subjects with advanced immunodeficiency syndrome who are presenting with acute AIDS-related opportunistic infection (OIs) or serious bacterial infections (BIs). There will be two steps and two arms in this study. All subjects will enter Step 1 and be randomized either to receive ART within 14 days after starting therapy for the acute OI/BI ("immediate" group or Arm A) or to have ART deferred ("deferred" group or Arm B).